Table 3.

Potential target agents identified based on protein-protein interaction networks of deregulated genes in infantile hemangioma

Gene symbol	Gene name	Selected target agent	Clinical relevance
EDNRA	endothelin receptor type A	Zibotentan, Atrasentan	Colorectal [62], prostate [63] and renal cell [64] carcinomas
IGF1R	insulin-like growth factor 1 receptor	Linsitinib, Ganitumab, Figitumumab, Dalotuzumab, Cixutumumab, Robatumumab	Adrenocortical [65], ovarian [66], non-small cell lung [67], colorectal [68, 69] carcinomas and soft tissue sarcoma [70]
PDGFC	platelet derived growth factor C	Sunitinib	Renal cell carcinoma [71] and breast carcinomas [72]
PDGFRA	platelet-derived growth factor receptor, alpha polypeptide	Motesanib, Ramucirumab, Midostaurin, Amuvatinib, Nintedanib, Pazopanib, Tandutinib, Crenolanib, Nilotinib, Masitinib, Sorafenib, Sunitinib, Regorafenib, Dovitinib, Telatinib, Vatalanib, Axitinib, Lenvatinib, Imatinib	Colorectal [73, 74], hepatocellular [75–78], kidney [79], non-small [80] and small cell lung [81], pancreatic [82–84], colon [85], gastrointestinal [86], renal cell [71, 87], breast [72, 88], melanoma [89], thyroid [90] carcinomas and soft tissue sarcoma [91]
VEGFA	vascular endothelial growth factor A	Ziv-aflibercept, Bevacizumab, Sorafenib tosylate, Lenalidomide, Thalidomide, Aflibercept	Colorectal [92, 93] ovarian [94], non-small cell lung [95], hepatocellular [96] carcinomas and multiple myeloma [97]